Page 53 - Read Online

Page 669 Sooi et al. Cancer Drug Resist 2023;6:656-73 https://dx.doi.org/10.20517/cdr.2023.48

analysis. PLoS One 2016;11:e0164514. DOI PubMed PMC
14. Gonda K, Shibata M, Ohtake T, et al. Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses,
malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol Lett 2017;14:1766-74. DOI PubMed PMC
15. Liu G, Lu S, Wang X, et al. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest
2013;123:4410-22. DOI PubMed PMC
16. Wensveen FM, Jelenčić V, Polić B. NKG2D: a master regulator of immune cell responsiveness. Front Immunol 2018;9:441. DOI
PubMed PMC
17. Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune
checkpoint inhibitors. J Immunother Cancer 2018;6:157. DOI PubMed PMC
18. Cai L, Michelakos T, Yamada T, et al. Defective HLA class I antigen processing machinery in cancer. Cancer Immunol Immunother
2018;67:999-1009. DOI PubMed PMC
19. Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage and repair biomarkers of immunotherapy response.
Cancer Discov 2017;7:675-93. DOI PubMed PMC
20. Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung
cancer. Science 2015;348:124-8. DOI PubMed PMC
21. Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma.
Cell 2016;165:35-44. DOI PubMed PMC
22. Strickland KC, Howitt BE, Shukla SA, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen
load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget
2016;7:13587-98. DOI PubMed PMC
23. McAlpine JN, Porter H, Köbel M, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune
cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol 2012;25:740-50. DOI PubMed
24. Clarke B, Tinker AV, Lee CH, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor
type, and BRCA1 loss. Mod Pathol 2009;22:393-402. DOI PubMed
25. Chung JH, Dewal N, Sokol E, et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO
Precis Oncol 2019;3:1-23. DOI PubMed PMC
26. Rodrigues DN, Rescigno P, Liu D, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects
in prostate cancer. J Clin Invest 2018;128:4441-53. DOI PubMed PMC
27. Antonarakis ES, Isaacsson Velho P, Fu W, et al. CDK12-altered prostate cancer: clinical features and therapeutic outcomes to
standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precis Oncol 2020;4:370-81. DOI
PubMed PMC
28. Alme AKB, Karir BS, Faltas BM, Drake CG. Blocking immune checkpoints in prostate, kidney, and urothelial cancer: an overview.
Urol Oncol 2016;34:171-81. DOI PubMed PMC
29. Goswami S, Aparicio A, Subudhi SK. Immune checkpoint therapies in prostate cancer. Cancer J 2016;22:117-20. DOI PubMed
PMC
30. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity
1994;1:405-13. DOI PubMed
31. Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of
intratumoral regulatory T cells. Cancer Immunol Res 2013;1:32-42. DOI PubMed
32. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant
prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3
trial. Lancet Oncol 2014;15:700-12. DOI
33. Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or
minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 2017;35:40-7.
DOI PubMed
34. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-47. DOI
PubMed
35. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
DOI PubMed
36. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop
signal. Nat Immunol 2009;10:1185-92. DOI PubMed PMC
37. Raedler LA. Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am
Health Drug Benefits 2015;8:180-3. PubMed PMC
38. Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell
lung cancer with progression on or after platinum-based chemotherapy. Oncologist 2016;21:634-42. DOI PubMed PMC
39. Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate
cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 2020;38:395-405. DOI PubMed PMC
40. Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
Ann Oncol 2018;29:1807-13. DOI PubMed